Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2015

Open Access 01-12-2015 | Research article

Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9

Authors: Marta Hernandez, Angels Mollo, Josep Ramon Marsal, Aureli Esquerda, Ismael Capel, Manel Puig-Domingo, Paolo Pozzilli, Alberto de Leiva, Didac Mauricio, on behalf of the Action LADA consortium

Published in: BMC Endocrine Disorders | Issue 1/2015

Login to get access

Abstract

Background

The study of endogenous insulin secretion may provide relevant insight into the comparison of the natural history of adult onset latent autoimmune diabetes (LADA) with types 1 and 2 diabetes mellitus. The aim of this study was to compare the results of the C-peptide response to mixed-meal stimulation in LADA patients with different disease durations and subjects with type 2 and adult-onset type 1 diabetes.

Methods

Stimulated C-peptide secretion was assessed using the mixed-meal tolerance test in patients with LADA (n = 32), type 1 diabetes mellitus (n = 33) and type 2 diabetes mellitus (n = 30). All patients were 30 to 70 years old at disease onset. The duration of diabetes in all groups ranged from 6 months to 10 years. The recruitment strategy was predefined to include at least 10 subjects in the following 3 disease onset categories for each group: 6 to 18 months, 19 months to 5 years and 5 to 10 years.

Results

At all time-points of the mixed-meal tolerance test, patients with LADA had a lower stimulated C-peptide response than the type 2 diabetes group and a higher response than the type 1 diabetes group. The same results were found when the peak or area under the C-peptide curve was measured. When the results were stratified by time since disease onset, a similar pattern of residual insulin secretory capacity was observed.

Conclusions

The present study shows that the magnitude of stimulated insulin secretion in LADA is intermediate between that of type 1 and type 2 diabetes mellitus.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stenström G, Gottsätter A, Bakhtadze E, Berger B, Sundkvist G: Latent autoimmune diabetes in adults. Definition, prevalence, β-cell function, and treatment.Diabetes 2005,54(Suppl2):S68–72.CrossRefPubMed Stenström G, Gottsätter A, Bakhtadze E, Berger B, Sundkvist G: Latent autoimmune diabetes in adults. Definition, prevalence, β-cell function, and treatment.Diabetes 2005,54(Suppl2):S68–72.CrossRefPubMed
2.
go back to reference Carlsson A, Sundqvist G, Groop L, Tuomi T: Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA).J Clin Endocrinol Metab 2000, 85:76–80.PubMed Carlsson A, Sundqvist G, Groop L, Tuomi T: Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA).J Clin Endocrinol Metab 2000, 85:76–80.PubMed
3.
go back to reference Hosszúfalusi N, Vatay A, Rajczy K, Prohászka Z, Pozsonyi E, Horváth L, et al.: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression.Diabetes Care 2003, 26:452–7. 10.2337/diacare.26.2.452CrossRefPubMed Hosszúfalusi N, Vatay A, Rajczy K, Prohászka Z, Pozsonyi E, Horváth L, et al.: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression.Diabetes Care 2003, 26:452–7. 10.2337/diacare.26.2.452CrossRefPubMed
4.
go back to reference Yang L, Zhou Z-G, Huang G, Ouyang L-L, Li X, Yan X: Six-year follow-up of pancreatic β-cell function in adults with latent autoimmune diabetes.World J Gastroenterol 2005, 11:2900–5.CrossRefPubMedPubMedCentral Yang L, Zhou Z-G, Huang G, Ouyang L-L, Li X, Yan X: Six-year follow-up of pancreatic β-cell function in adults with latent autoimmune diabetes.World J Gastroenterol 2005, 11:2900–5.CrossRefPubMedPubMedCentral
5.
go back to reference Chaillous L, Bouhanick B, Kerlan V, Mathieu E, Lecomte P, Ducluzeau PH, et al.: Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control.Diabetes Metab 2010, 36:64–70. doi:10.1016/j.diabet.2009.07.004 10.1016/j.diabet.2009.07.004CrossRefPubMed Chaillous L, Bouhanick B, Kerlan V, Mathieu E, Lecomte P, Ducluzeau PH, et al.: Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control.Diabetes Metab 2010, 36:64–70. doi:10.1016/j.diabet.2009.07.004 10.1016/j.diabet.2009.07.004CrossRefPubMed
6.
go back to reference Lee SA, Lee WJ, Kim EH, Yu JH, Jung CH, Koh EH, et al.: Progression to insulin deficiency in Korean patients with type 2 diabetes mellitus positive for anti-GAD antibody.Diabet Med 2011, 28:319–24. doi:10.1111/j.1464–5491.2010.03186.xCrossRefPubMed Lee SA, Lee WJ, Kim EH, Yu JH, Jung CH, Koh EH, et al.: Progression to insulin deficiency in Korean patients with type 2 diabetes mellitus positive for anti-GAD antibody.Diabet Med 2011, 28:319–24. doi:10.1111/j.1464–5491.2010.03186.xCrossRefPubMed
7.
go back to reference Thunander M, Thorgeirsson H, Törn C, Petersson C, Landin-Olsson M: ß-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up.Eur J Endocrinol 2011, 164:239–45. doi:10.1530/EJE-10–0901 10.1530/EJE-10-0901CrossRefPubMedPubMedCentral Thunander M, Thorgeirsson H, Törn C, Petersson C, Landin-Olsson M: ß-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up.Eur J Endocrinol 2011, 164:239–45. doi:10.1530/EJE-10–0901 10.1530/EJE-10-0901CrossRefPubMedPubMedCentral
8.
go back to reference Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, et al.: Latent autoimmune diabetes (LADA) is perched between type 1 and type 2: evidence from adults in one region of Spain.Diab Metab Res Rev 2013, 29:693. doi:10.1002/dmrr.2411CrossRef Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, et al.: Latent autoimmune diabetes (LADA) is perched between type 1 and type 2: evidence from adults in one region of Spain.Diab Metab Res Rev 2013, 29:693. doi:10.1002/dmrr.2411CrossRef
9.
go back to reference Greenbaum CJ, Harrison LC: Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.Diabetes 2003, 52:1059–65. 10.2337/diabetes.52.5.1059CrossRefPubMed Greenbaum CJ, Harrison LC: Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.Diabetes 2003, 52:1059–65. 10.2337/diabetes.52.5.1059CrossRefPubMed
10.
go back to reference Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, et al.: Time to insulin initiation cannot be used in defining latent autoimmune diabetes of the adult.Diabetes Care 2008, 31:439–41. 10.2337/dc07-1308CrossRefPubMed Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, et al.: Time to insulin initiation cannot be used in defining latent autoimmune diabetes of the adult.Diabetes Care 2008, 31:439–41. 10.2337/dc07-1308CrossRefPubMed
11.
go back to reference Palomer X, Mauricio D, Rodríguez-Espinosa J, Zapico E, Mayoral C, González-Sastre F, et al.: Evaluation of two nonisotopic immunoassays for determination of glutamic acid decarboxylase and tyrosine phosphatase autoantibodies in serum.Clin Chem 2004, 50:1378–82. 10.1373/clinchem.2004.031799CrossRefPubMed Palomer X, Mauricio D, Rodríguez-Espinosa J, Zapico E, Mayoral C, González-Sastre F, et al.: Evaluation of two nonisotopic immunoassays for determination of glutamic acid decarboxylase and tyrosine phosphatase autoantibodies in serum.Clin Chem 2004, 50:1378–82. 10.1373/clinchem.2004.031799CrossRefPubMed
12.
go back to reference Chen S, Willis J, Maclean C, Ananieva-Jordanova R, Amoroso MA, Brooking H, et al.: Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65.Cin Chim Acta 2005, 357:74–83. 10.1016/j.cccn.2005.02.006CrossRef Chen S, Willis J, Maclean C, Ananieva-Jordanova R, Amoroso MA, Brooking H, et al.: Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65.Cin Chim Acta 2005, 357:74–83. 10.1016/j.cccn.2005.02.006CrossRef
13.
go back to reference Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, et al.: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.Diabetes Care 2008, 31:1966–71. 10.2337/dc07-2451CrossRefPubMedPubMedCentral Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, et al.: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.Diabetes Care 2008, 31:1966–71. 10.2337/dc07-2451CrossRefPubMedPubMedCentral
Metadata
Title
Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9
Authors
Marta Hernandez
Angels Mollo
Josep Ramon Marsal
Aureli Esquerda
Ismael Capel
Manel Puig-Domingo
Paolo Pozzilli
Alberto de Leiva
Didac Mauricio
on behalf of the Action LADA consortium
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2015
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-15-1

Other articles of this Issue 1/2015

BMC Endocrine Disorders 1/2015 Go to the issue